Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

BACKGROUND: Ovarian cancer is the most fatal gynecologic malignancy in the United States. While chemotherapy is effective in the vast majority of ovarian cancer patients, recurrence and resistance to standard systemic therapy is nearly inevitable. We discovered that activation of the non-receptor ty...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Ovarian Res
Main Authors: Crean-Tate, Katie K., Braley, Chad, Dey, Goutam, Esakov, Emily, Saygin, Caner, Trestan, Alexandria, Silver, Daniel J., Turaga, Soumya M., Connor, Elizabeth V., DeBernardo, Robert, Michener, Chad M., Rose, Peter G., Lathia, Justin, Reizes, Ofer
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8063392/
https://ncbi.nlm.nih.gov/pubmed/33888137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-021-00797-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados